Clinical Research Details

Descriptive Information
Character Strengths of women with Polycystic Ovary Syndrome and the role of testosterone: A case-control study.

Ghina Ghazeeri
gg02@aub.edu.lb

OGY.GG.17 / SBS-2017-0491
Recruiting

Clinical Research - Epidemiologic and Behavioral Studies  


No
Collaborators
  • Dalia Khalifeh
Coordinators
Christine Beyrouthy
cb37@aub.edu.lb
Extension: 5618
Conditions and Keywords
character strength,Polycystic ovary syndrome
oersonality,polycystic ovary syndrome
Study Design
Health Services Research
N/A: Not Applicable
Observational Study
N/A: Not Applicable
N/A: Not Applicable
N/A: Not Applicable
Case Control
Eligibility and IRB
Female
Min: 18
Max: 45
Yes
No

This is an exploratory observational case-control study. The main objective of this study is to show whether there is a specific positive personality profile for patients with PCOS.







Parti


Participants are selected by the principle investigator from gynecological clinics at the women’s center in AUBMC. The patients will be approached by their gynecologists after they identify potential participants who meet the study criteria and will be either with PCOS or normal fertile controls.

Purposive sampling


-      Adult females of child bearing age: 18-45 years old

-      Women who meet the Rotterdam criteria for PCOS according to the revised 2003 criteria (2 out of 3) 1. Oligo- or anovulation, 2. Clinical and/or biochemical signs of hyperandrogenism, 3.      Polycystic ovaries (ESHRE & ASRM-Sponsored PCOS Consensus Workshop Group, 2004).


-      Any known physical disability or severe mental and psychological disorders or trauma and history of any psychotic disorders such as schizophrenia. Reaches the cut off of the Hospital Anxiety and Depression scale (HADS) which assesses psychological distress.

-      Endocrine disorders including: congenital adrenal hyperplasia, Cushing’s syndrome, menopause, androgen secreting tumors (Barry et al., 2013).

-      Participants with: thyroid dysfunction, hyperaprolactinemia, type 2 diabetes mellitus, concomitant cardiovascular disease, liver and renal dysfunction (Scaruffi, Gambineri, Cattaneo, Turra, Vettor, & Mioni, 2014).